Hosted on MSN1d
4.75 cr screened for sickle cell anaemia, 0.38 pc diagnosed with disorder: Health Minister NaddaMore than 4.75 crore people, including 1,98,62,568 tribal persons living in the tribal-dominated areas across 17 identified ...
The target of eliminating Sickle Cell Anemia, a disease common in tribal communities, from tribal society is included under the goal of building a developed India by the year 2047, she underlined. She ...
Sickle cell anemia requires ongoing, lifelong treatment to improve quality of life and prevent complications. Treatment of sickle cell anemia includes taking measures to treat anemia, prevent ...
It's common knowledge that our brains—and, specifically, our brain cells—store memories. But a team of scientists has discovered that cells from other parts of the body also perform a memory ...
Living with sickle cell disease is not a proverbial bed of roses; instead, it’s a journey of twists and turns. Yet I’m grateful for the experience. It’s imparted invaluable life lessons that have ...
Beam Therapeutics (Nasdaq: BEAM) will detail new clinical and pre-clinical data on its sickle cell disease (SCD) therapies at the upcoming American Society of Hematology (ASH) meeting. The biotech ...
Beam Therapeutics gave an initial look at the first handful of patients who received its experimental gene-edited treatment for sickle cell disease.
Novo Nordisk’s once-a-day sickle cell disease drug etavopivat cut the rate of pain crises in a yearlong mid-stage study.
It’s a rare condition triggered by exercise that is too intense in someone with the sickle cell trait, a sickle cell gene inherited from just one parent. Such exercise can cause the body’s red blood ...
No vaso-occlusive crises (VOCs, painful complication of sickle cell anemia) were reported by investigators following BEAM-101 treatment. Beam Therapeutics said patient enrollment in the Phase 1/2 ...
A patient with sickle cell disease died while participating in a clinical trial of a CRISPR-based treatment from Beam Therapeutics, threatening to overshadow early signals of effective gene editing.
Beam’s medicine uses a technology known as base editing to activate a gene in stem cells collected from people with sickle cell disease, an inherited blood condition that can cause debilitating pain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback